ATE224442T1 - Zielgerichtetes einbringen eines virus-vektors in säugetierzellen. - Google Patents

Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.

Info

Publication number
ATE224442T1
ATE224442T1 AT92922980T AT92922980T ATE224442T1 AT E224442 T1 ATE224442 T1 AT E224442T1 AT 92922980 T AT92922980 T AT 92922980T AT 92922980 T AT92922980 T AT 92922980T AT E224442 T1 ATE224442 T1 AT E224442T1
Authority
AT
Austria
Prior art keywords
pct
virus
virus vector
mammal cells
targeted introduction
Prior art date
Application number
AT92922980T
Other languages
English (en)
Inventor
Leif Lindholm
Sven Enerbaeck
Oerjan Strannegard
Original Assignee
Got A Gene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20384166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE224442(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Got A Gene Ab filed Critical Got A Gene Ab
Application granted granted Critical
Publication of ATE224442T1 publication Critical patent/ATE224442T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT92922980T 1991-10-30 1992-10-28 Zielgerichtetes einbringen eines virus-vektors in säugetierzellen. ATE224442T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103183A SE503225C2 (sv) 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller
PCT/SE1992/000745 WO1993009221A1 (en) 1991-10-30 1992-10-28 Targeted delivery of virus vector to mammalian cells

Publications (1)

Publication Number Publication Date
ATE224442T1 true ATE224442T1 (de) 2002-10-15

Family

ID=20384166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92922980T ATE224442T1 (de) 1991-10-30 1992-10-28 Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.

Country Status (9)

Country Link
US (1) US5695991A (de)
EP (1) EP0614486B1 (de)
JP (1) JPH07502026A (de)
AT (1) ATE224442T1 (de)
CA (1) CA2122613C (de)
DE (1) DE69232782T2 (de)
ES (1) ES2180538T3 (de)
SE (1) SE503225C2 (de)
WO (1) WO1993009221A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
CA2224907A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
KR100353115B1 (ko) 1995-11-13 2003-01-06 다카라츠죠 가부시키가이샤 레트로바이러스를사용한표적세포내로의유전자도입방법
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
EP0927044A4 (de) * 1996-04-16 1999-09-08 Immusol Inc Gerichtete viral vektoren
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
DE19649645A1 (de) * 1996-11-29 1998-06-04 Hoechst Ag Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
WO1998044938A1 (en) 1997-04-10 1998-10-15 University Of Southern California Modified proteins which bind extracellular matrix components
AU7127798A (en) * 1997-04-18 1998-11-13 President And Fellows Of Harvard College Bifunctional polypeptides for cell-specific viral targeting
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
AU2662999A (en) * 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
US20060292121A1 (en) * 1998-04-29 2006-12-28 Hall Frederick L Retroviral vectors including modified envelope escort protein
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
AU4070499A (en) 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
US6060316A (en) * 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
WO2001092549A2 (en) * 2000-05-31 2001-12-06 Genvec, Inc. Method and composition for targeting an adenoviral vector
DK1372708T3 (da) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US11266736B2 (en) 2008-04-17 2022-03-08 Vin De Bona Trading Company Pte Ltd Method of painting micro vesicles
EP2281033B1 (de) 2008-04-17 2014-10-15 Vin de Bona Trading Co Pte Modifizierung viraler hüllen nach deren freisetzung
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
IL270024B2 (en) 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
EP3793595A1 (de) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Verbesserte lamp-konstrukte mit allergenen
JP2022551732A (ja) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド がん抗原を含む改良ｌａｍｐ構築物
EP4508071A1 (de) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronische lampenkonstrukte mit immunreaktionserhöhenden genen und verfahren zur verwendung davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364934A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
WO1989007136A2 (en) * 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
JPH04504361A (ja) * 1989-04-05 1992-08-06 ノバセル　コーポレイション 感染性標的化複製―欠陥ビリオン
FR2649119A1 (fr) * 1989-06-30 1991-01-04 Centre Nat Rech Scient Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
AU648261B2 (en) * 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
CA2092323A1 (en) * 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller

Also Published As

Publication number Publication date
EP0614486B1 (de) 2002-09-18
WO1993009221A1 (en) 1993-05-13
JPH07502026A (ja) 1995-03-02
DE69232782D1 (de) 2002-10-24
SE503225C2 (sv) 1996-04-22
SE9103183L (sv) 1993-05-01
SE9103183D0 (sv) 1991-10-30
EP0614486A1 (de) 1994-09-14
US5695991A (en) 1997-12-09
ES2180538T3 (es) 2003-02-16
CA2122613A1 (en) 1993-05-13
CA2122613C (en) 2003-08-19
DE69232782T2 (de) 2003-02-20

Similar Documents

Publication Publication Date Title
ATE224442T1 (de) Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.
MY104946A (en) Antigen antibody conjugate.
GB2361921B (en) Herpes virus vectors for dendritic cells
EP0643131A3 (de) Vorrichtung zum Sammeln und in-vitro-Transport von Proben, insbesondere für Diagnoseverwendungen.
ES2034929T1 (es) Un sistema de transferencia de valores.
IL114444A (en) Kit for inducing immune response against a tumor or a disease caused by an infectious agent
ES2161875T3 (es) Celulas con multiples epitopos alterados en un antigeno superficial para uso en transplantes.
DK0807178T3 (da) Mycobaktielle proteiner, mikroorganismer producerende samme og anvendelser af nævnte proteiner i vacciner og til påvisning af tuberkulose
PT649537E (pt) Imunoanalises para anticorpos anti-vhc utilizando antigenios com epitopos conformacionais
DE69021953D1 (de) Enzymimmuntest für Antigene und dafür verwendbare feste Phase.
FI932912A0 (fi) Testmetod och reagensfoerpackning avsedd foer den
MY100476A (en) Supported viral antigen and preparation and use thereof
ATE210753T1 (de) Mehrzweck-trägergerät
SE9102014D0 (sv) Foerfarande i samband med mammalieceller
GR77981B (de)
Deans Molecular and functional analysis of CD45 in T cell development
PT650523E (pt) Antigene cdw52 recombinante
HOJO Intensive Report from Respective Parts of Research on “Buddhism and Anthropology”
IT1264078B1 (it) Uso di anticorpi anti-molecole hla classe i libere da beta-2 microglobulina per saggi di evidenziazione dell'esposizione al virus
IT9006602A0 (it) Test immunoenzimatico per la ricerca e determinazione degli anticorpi anti-ss-dna.
ATE95312T1 (de) Waschzusammensetzung, testsatz und ihre verwendung zur bestimmung eines viralen antigens aus herpes simplex.
CS298787A3 (en) Micro-titrimetric plate for enzymoimmunological test for the detection of antibodies against nuclear antigen of epstain and barrow virus
IT1262976B (it) Oligonucleotidi antisenso e loro uso

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties